Superficial Punctate Keratoepitheliopathy Under Treatment with Erlotinib and Lapatinib
Journal of the Korean Ophthalmological Society
;
: 293-297, 2014.
Article
in Korean
| WPRIM
| ID: wpr-90221
ABSTRACT
PURPOSE:
To report the corneal superficial punctate keratoepitheliopathy in 2 patients taking the epidermal growth factor receptor (EGFR) inhibitors, erlotinib and lapatinib, respectively. CASESUMMARY:
Case 1, who received erlotinib, showed trichomegaly without touching the cornea and diffuse punctate keratoepitheliopathy. Corneal epitheliopathy and the corresponding symptoms resolved after discontinuation of the drug then recurred with reapplication. Case 2 presented diffuse corneal punctate epithelial erosions that developed without any cilia involvement after the patient was administered lapatinib. The visual acuity of both patients was not severely diminished and keratoepitheliopathy was mostly resolved with the treatment of preservative-free artificial tears and autologous serum eye drops.CONCLUSIONS:
Erlotinib and lapatinib are both likely to cause visually tolerable corneal punctate keratoepitheliopathy which can be resolved with appropriate topical treatment.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Ophthalmic Solutions
/
Visual Acuity
/
Cilia
/
Cornea
/
Epidermal Growth Factor
/
ErbB Receptors
/
Erlotinib Hydrochloride
Limits:
Humans
Language:
Korean
Journal:
Journal of the Korean Ophthalmological Society
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS